↠Research library / Metabolic
Retatrutide has produced some of the most impressive weight loss results ever recorded in clinical trials. It is also not approved in any country on earth, and Eli Lilly does not plan to submit it for US approval until Q1 2027.
That combination, extraordinary demand, zero legal supply, is precisely why gray-market sellers stock it in seven different strengths. Every vial of retatrutide for sale online today is unapproved, unregulated, and of unverifiable origin. There is no legitimate consumer supply, at any price, from any seller.
We can't sell you this. Nobody legally can. This page exists so you can understand what it actually is.
Most GLP-1 medications target one receptor. Tirzepatide targets two, GIP and GLP-1. Retatrutide targets three, adding glucagon receptor agonism. The glucagon component is thought to contribute additional energy expenditure alongside the appetite and glycemic effects of the other two.
| Trial | Population | Result |
|---|---|---|
| TRANSCEND-T2D-1 | Type 2 diabetes | A1C reduction up to 2.0%; weight loss up to an average of 36.6 lbs (16.8%) at 40 weeks[1] |
| TRIUMPH-2 & TRIUMPH-3 | Obesity with T2D or established CVD | Met primary endpoints; substantial weight loss in patients with serious complications[2] |
| TRIUMPH-4 | Obesity with osteoarthritis | 28.7% average weight loss at highest dose, with substantial improvements in pain and physical function[3] |
Across five positive Phase 3 studies, Lilly has described retatrutide as showing powerful efficacy and a potential future tool in cardiometabolic management.[2]
Lilly is completing the Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application, and plans to submit for US approval in Q1 2027.[1] Approval, if granted, would follow FDA review after that.
Until then it is an investigational drug. Not off-label, investigational. Off-label prescribing means using an approved drug for an unapproved purpose. Retatrutide has no approved purpose anywhere, so there is no label to be "off" of.
With approved drugs, gray-market versions at least have a known reference product. With retatrutide there is no legitimate finished product in existence anywhere in the world. Whatever is being sold is manufactured by an unregistered facility, to unknown standards, with no regulatory oversight of any kind.
See Safety & sourcing.
Clinical trials are the only legal route. Search ClinicalTrials.gov for retatrutide studies recruiting in your area. Trial participation gets you the actual drug, actual monitoring, and no cost, which is a considerably better deal than the gray market on every axis.
No. Selling an unapproved investigational drug for human use violates federal law regardless of how the label is worded. "Research use only" language on a product marketed to consumers has historically been treated by regulators as evidence of knowledge, not as a defense.
Lilly plans to submit in Q1 2027, and FDA review follows submission. Nobody can give you a firm approval date, and anyone who does is guessing.
If approved and appropriate for a given patient, we'd work within whatever the approved channel turns out to be. We'll update this page when there's something real to say.
Primary sources from the sponsor. Not affiliated with or endorsed by us.
Full library · Safety & sourcing